Literature DB >> 10820341

A clinicopathologic study of gastric mucosa-associated lymphoid tissue lymphoma.

S Ohashi1, K Segawa, S Okamura, H Urano, S Kanamori, H Ishikawa, K Hara, A Hukutomi, K Shirai, M Maeda.   

Abstract

BACKGROUND: It is still unclear which patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma will benefit from the eradication of Helicobacter pylori.
METHODS: The authors studied a total of 34 patients. Twenty-three patients had primary gastric lymphoma and underwent gastric resection as initial treatment. Eleven patients with gastric MALT lymphoma who received antibiotics against H. pylori as initial treatment were also included. In all 34 patients, the presence of H. pylori, endoscopic findings, and pathologic features were evaluated. Immunohistochemical expression of Bcl-2, p53, and proliferating cell nuclear antigen (PCNA) was classified as follows: (-), no reactive cells; (+), scattered positive cells; (2+), nests of positive cells; (3+), diffuse positive cells.
RESULTS: Patients with low grade MALT lymphoma (LG) tended to be positive for H. pylori (6 of 9), to localize within the submucosa (7 of 9), not to have lymph node involvement (7 of 8), and to have lower tumor stage compared with patients with high grade MALT components (HG). Bcl-2 protein was expressed with high frequency by LG (7 of 9). Strong expression of p 53 was more common in the HG tumors (4 of 14), and strong expression of PCNA showed a significant difference between LG (1 of 8) and HG patients (12 of 13). Investigation of the patients with long term follow-up (n = 4) revealed that LG remained superficial for a long time and showed gradual progression. Most of these tumors were Bcl-2+/p53-approximately+/-/ PCNA- approximately +. There were two patients whose superficial LG (sm/Bcl-2+/p53-/PCNA- approximately +) regressed after the disappearance of H. pylori. On the other hand, one patient developed ulcerated LG (sm/Bcl-2 /p53+/PCNA3+) after disappearance of H. pylori. The authors found complete regression of MALT lymphoma in 9 of 11 patients after H. pylori eradication. Initial tumors of these 9 patients were superficial/sm/n(-)/low grade/Bcl-2+approximately +/-/p53-approximately+ (n = 9), /PCNA-approximately+(n = 6), /PCNA 2+ (n = 3). Two local recurrence and one non-Hodgkin lymphoma in other sites were observed after initial therapy.
CONCLUSIONS: Gastric MALT lymphoma with (H. pylori positive/superficial/sm/low grade/Bcl-2 +/p53- approximately +/PCNA- approximately +) pattern will disappear after a patient is cured of H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820341     DOI: 10.1002/(sici)1097-0142(20000515)88:10<2210::aid-cncr3>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Correlation between immunophenotype classification and clinicopathological features in chinese patients with primary gastric diffuse large B-cell lymphoma.

Authors:  Zhang Zizhen; Cao Hui; Shen Yanying; Shen Danping; Liu Jiahua; He Chao; Ni Xingzhi
Journal:  Pathol Oncol Res       Date:  2012-12-14       Impact factor: 3.201

2.  p27kip1 expression is inversely related to the grade of gastric MALT lymphoma.

Authors:  Haim Shirin; Vladimir Kravtsov; Mark Shahmurov; Paulina Petchenko; Mona Boaz; Steven F Moss; Yona Avni; Ilana Avinoach
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 3.  Helicobacter and gastric MALT lymphoma.

Authors:  M Stolte; E Bayerdörffer; A Morgner; B Alpen; T Wündisch; C Thiede; A Neubauer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

4.  Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Hong-Ling Li; Bing-Zhong Sun; Fu-Cheng Ma
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

Review 5.  Therapy of gastric mucosa associated lymphoid tissue lymphoma.

Authors:  Andrea Morgner; Renate Schmelz; Christian Thiede; Manfred Stolte; Stephan Miehlke
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

6.  Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Authors:  An Mt Van Nuffel; Vidula Sukhatme; Pan Pantziarka; Lydie Meheus; Vikas P Sukhatme; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2015-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.